Chemoradiotherapies induce PD-L1 expression on lung tumor cells and T cell tumor infiltration (14), while NF-κB2 knockout/knockdown in AMs and TAMs boosts T cells, providing a basis for their combination with each other and PD-L1 blockade therapy for lung cancer treatment. The gene discussed is NFKB2; the disease is lung carcinoma.